PRESS-RELEASE ·Filed Apr 29, 2026
Press release: earnings
Actionable Insight ▼ Bearish
The EPS miss suggests near-term headwinds. Monitor the earnings call for guidance on product revenue and pipeline progress to gauge if the miss is transient or structural.
Final — all horizons settled through T+60d
URGN ▲ +75.54% at T+60d
SHORT call ✗ call lost -75.54% · α vs SPY -71.42% · entry $23.34 → $40.97
T+1d
+2.10%
call -2.10% · α -1.08%
$23.83
settled 5mo ago
T+5d
+2.10%
call -2.10% · α +1.01%
$23.83
settled 5mo ago
T+20d
+25.66%
call -25.66% · α -20.20%
$29.33
settled 4mo ago
T+60d
+75.54%
call -75.54% · α -71.42%
$40.97
settled 2mo ago
Price Chart
Loading chart...
Executive Summary
UroGen Pharma reported Q4 2025 EPS of -$0.54, missing consensus of -$0.48 by 12.5%. No revenue figure was disclosed in the filing. The miss reflects ongoing operational challenges and may pressure near-term sentiment.
Key Financial Metrics
EPS
$-0.54
est $-0.48 · -12.5%
Rating
strong miss
Key Facts
- Q4 2025 EPS -$0.54 vs consensus -$0.48 (12.5% miss)
- No revenue actual provided in the filing
- Earnings call scheduled for May 6, 2026
Financial Impact
EPS miss of $0.06 per share vs consensus, a 12.5% negative surprise
eps
Risk Factors
- Potential downward revision of forward estimates
- Dependence on key product launches for revenue growth
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (14 analysts)
Investment Themes
Biotech & Drug Discovery
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3283688 |
9 reports for URGN
100% Hit rate best @ T+60▲ +54.89%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | Insider Cluster | $45.00 $43.04 | ▼ −4.36% | ▼ −4.02% | $41.40 (−8.00%) |
Aug 20, 2026 6w ago | 8-K | $46.80 $45.50 | ▼ −2.78% | ▼ −3.89% | $41.40 (−11.54%) |
Aug 5, 2026 8w ago | 8-K | $46.43 $49.00 | ▲ +5.54% | ▲ +5.18% | $41.40 (−10.83%) |
Jun 23, 2026 14w ago | 8-K | $35.42 $37.94 | ▲ +7.11% | ▲ +5.41% | $41.40 (+16.88%) |
Jun 2, 2026 17w ago | 8-K | $26.54 $28.18 | ▲ +6.18% | ▲ +9.14% | $41.40 (+55.99%) |
May 6, 2026 21w ago | Press Release | $26.25 $29.80 | ▲ +13.52% | ▲ +12.39% | $41.40 (+57.71%) |
Apr 29, 2026 22w ago | Press Release | $23.34 $23.83 | ▼ −2.10% | ▲ +1.01% | $41.40 (−77.38%) |
Mar 2, 2026 30w ago | Press Release | $19.02 $19.91 | ▲ +4.68% | ▲ +5.89% | $41.40 (+117.67%) |
Mar 2, 2026 30w ago | Press Release | $19.02 $19.91 | ▲ +4.68% | ▲ +5.89% | $41.40 (+117.67%) |
Showing 9 of 9
US Market Status
Market Closed — Opens Mon (65h 5m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access